Targeted-release budesonide therapy for IgA nephropathy - Authors' reply

Affiliations

¹ Department of Medical Sciences, Renal Unit, Uppsala University Hospital, Uppsala, S-75185 Sweden. Electronic address: bengt.fellstrom@medsci.uu.se.
² Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK; John Walls Renal Unit, Leicester General Hospital, Leicester, UK; Postgraduate Specialty School of Clinical Academic Training, Health Education East Midlands, Leicester, UK.
³ Medizinische Klinik II, RWTH Aachen Univeristy, Aachen, Germany.
⁴ Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland; Glasgow Renal Transplant Unit, Queen Elizabeth Hospital, Glasgow, Scotland.

Comment

Bengt Fellström et al. Lancet. 2017.

. 2017 Dec 16;390(10113):2625-2626.

doi: 10.1016/S0140-6736(17)32138-4.

¹ Department of Medical Sciences, Renal Unit, Uppsala University Hospital, Uppsala, S-75185 Sweden. Electronic address: bengt.fellstrom@medsci.uu.se.
² Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK; John Walls Renal Unit, Leicester General Hospital, Leicester, UK; Postgraduate Specialty School of Clinical Academic Training, Health Education East Midlands, Leicester, UK.
³ Medizinische Klinik II, RWTH Aachen Univeristy, Aachen, Germany.
⁴ Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland; Glasgow Renal Transplant Unit, Queen Elizabeth Hospital, Glasgow, Scotland.

No abstract available

Comment on

Targeted-release budesonide therapy for IgA nephropathy.
Tsuda K, Tanimoto T, Mori J, Kosugi K, Komatsu T. Tsuda K, et al. Lancet. 2017 Dec 16;390(10113):2625. doi: 10.1016/S0140-6736(17)32145-1. Lancet. 2017. PMID: 29256403 No abstract available.